IP Library Granted Patent US 9,623,267
Granted Patent B2
US 9,623,267 · App. 12/717,818 · Granted Apr 18, 2017

Ultrasonic treatment of adipose tissue at multiple depths

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,623,267
App. No.
12/717,818
Granted
Apr 18, 2017
Kind
B2
Abstract

Methods and apparatus ( 100 ) are described for modifying unwanted tissue for cosmetic reasons. The methods provide a non-invasive manner to perform body contouring by destroying adipose tissue while simultaneously causing collagen contraction in a single procedure. Adipose tissue destroyed during the medical procedure may be removed from a treatment volume during the wound healing process, allowing the treatment volume to gradually shrink ( 22 ). The gradual shrinkage may promote better skin tone in the treatment area. The procedure may involve multiple treatments to the same treatment area or location.

Claims (73)

1. A method of modifying adipose tissue using high intensity focused ultrasound (HIFU), the method comprising:

determining a volume of adipose tissue to be treated;

identifying a corresponding surface area of skin over said volume of adipose tissue;

moving a therapy head including a HIFU therapy transducer on said surface area of skin; and

transferring the HIFU from the HIFU therapy transducer through a coupling fluid surrounding the HIFU therapy transducer to apply multiple treatments of therapeutic ultrasound energy into said volume of adipose tissue such that a plurality of necrosed tissue cells and denatured collagen fibrils are produced, the multiple treatments occurring at least at two different depths.

2. A method of reducing adipose tissue volume in a patient using high intensity focused ultrasound, the method comprising:

determining a volume of adipose tissue to be treated;

identifying a corresponding surface area of skin over said volume of adipose tissue; and

transferring the high intensity focused ultrasound from a transducer through a coupling fluid surrounding the transducer to apply multiple treatments of high intensity focused ultrasound energy to said area in a manner sufficient to induce the gradual destruction of said adipose tissue and denaturing of collagen fibrils, the energy flux of the multiple treatments being at least 35 J/cm 2 , and the multiple treatments occurring at least at two different depths.

3. A medical ultrasound therapy system for treating a volume of adipose tissue, comprising:

a therapy head including a first chamber, a coupling fluid in the first chamber, and at least one high intensity focused ultrasound transducer surrounded by the coupling fluid in the first chamber, the at least one high intensity focused ultrasound transducer configured to emit high intensity focused ultrasound from the at least one high intensity focused ultrasound transducer through the coupling fluid to the volume of adipose tissue; and

a controller comprising:

a data store storing information about a three dimensional treatment profile for the therapy head; and

a processor coupled to the data store, the processor generating a three dimensional treatment cycle for the therapy head in accordance with the information, the three dimensional treatment cycle including treatments by the therapy head at a plurality of different depths.

4. The system of claim 3 , wherein the therapy head comprises:

an enclosure with a partition, the partition defining the first chamber and a second chamber within the enclosure; and

a motor assembly within the second chamber,

wherein the high intensity focused ultrasound transducer is movable within the first chamber through motor commands provided to the motor assembly from the controller.

5. The system of claim 3 , wherein the data store further comprises information stored in library tables.

6. The system of claim 3 , wherein the data store further comprises profile data particular to various anatomical regions of adipose tissue.

7. The system of claim 6 , wherein the profile data is adapted for gender variations.

8. The system of claim 3 , wherein the therapy head is adapted for various anatomical regions of adipose tissue.

9. The system of claim 3 , wherein the controller is adapted to promote an effect of necrosis of adipose tissue.

10. The system of claim 3 , wherein the controller is adapted to promote an effect of denaturing collagen fibrils.

11. A medical ultrasound therapy system for treating a volume of adipose tissue, comprising:

a therapy head including a first chamber, a coupling fluid in the first chamber, and at least one high intensity focused ultrasound transducer surrounded by the coupling fluid in the first chamber, the at least one high intensity focused ultrasound transducer configured to emit high intensity focused ultrasound from the at least one high intensity focused ultrasound transducer through the coupling fluid to the volume of adipose tissue; and

a controller for generating a three dimensional treatment plan for the therapy head, the controller comprising:

a data access component for accessing data defining a three dimensional treatment profile for a treatment of a defined region of a patient, the treatment profile including information about treatments to be conducted at a plurality of different depths; and

a treatment plan component for generating a treatment plan based upon the treatment profile, the treatment plan including treatments defined for the therapy head at the plurality of different depths in accordance with the information.

12. The system of claim 11 , wherein the therapy head comprises:

an enclosure with a partition, the partition defining the first chamber and a second chamber within the enclosure; and

a motor assembly within the second chamber,

wherein the high intensity focused ultrasound transducer is movable within the first chamber through motor commands provided to the motor assembly from the controller.

13. The system of claim 11 , wherein the data store further comprises information stored in library tables.

14. The system of claim 11 , wherein the data store further comprises profile data particular to various anatomical regions of adipose tissue.

15. The system of claim 14 , wherein the profile data is adapted for gender variations.

16. The system of claim 11 , wherein the therapy head is adapted for various anatomical regions of adipose tissue.

17. The system of claim 11 , wherein the controller is adapted to promote an effect of necrosis of adipose tissue.

18. The system of claim 11 , wherein the controller is adapted to promote an effect of denaturing collagen fibrils.

19. A method for treating a patient with high intensity focused ultrasound, the method comprising:

positioning a therapy head having at least one high intensity focused ultrasound transducer against a first location on a patient; and

using an automated process:

while at the first location, transferring the high intensity focused ultrasound from the at least one high intensity focused ultrasound transducer through a coupling fluid to ablate the tissue at a first depth; and

while at the first location, transferring the high intensity focused ultrasound from the at least one high intensity focused ultrasound transducer through the coupling fluid in the therapy head to ablate tissue at a second depth.

20. The method of claim 19 , wherein the automated process comprises:

accessing information about a plurality of depths profile for the therapy head; and

generating a multi-depth treatment cycle for the therapy head in accordance with the information, the multi-depth treatment cycle including treatments by the therapy head at the plurality of depths.

21. The method of claim 20 , wherein the information is stored in library tables.

22. The method of claim 20 , wherein the information comprises profile data particular to various anatomical regions of adipose tissue.

23. The method of claim 19 , wherein the therapy head comprises:

an enclosure with a partition, the partition defining the first chamber and a second chamber within the enclosure; and

a motor assembly within the second chamber,

wherein the high intensity focused ultrasound transducer is movable within the first chamber through motor command provided to the motor assembly from the controller; and

wherein the automated process comprises the ultrasound transducer moving with the first chamber through motor command.

24. The method of claim 23 , wherein the profile data is adapted for gender variations.

25. The method of claim 23 , wherein depth variation is provided by varying the focus of the ultrasound transducer.

26. The method of claim 19 , wherein ablating tissue comprises promoting an effect of necrosis of adipose tissue.

27. The method of claim 19 , wherein ablating tissue comprises promoting promote an effect of denaturing collagen fibrils.

28. A medical ultrasound therapy system, comprising:

a therapy head including a first chamber, a coupling fluid in the first chamber, and at least one high intensity focused ultrasound transducer surrounded by the coupling fluid in the first chamber, the at least one high intensity focused ultrasound transducer configured to emit high intensity focused ultrasound from the at least one high intensity focused ultrasound transducer through the coupling fluid to the volume of adipose tissue; and

a controller comprising:

a data store having stored thereon a data structure, the data structure comprising a tissue ablation treatment routine comprising a first data field containing data representing a routine for first ablation of tissue at a first depth in accordance with the routine and a second data field representing a routine for second ablation of tissue at a second depth in accordance with the routine; and

a processor coupled to the data store, the processor accessing the data structure and instructing the therapy head to perform the routine in an automated process and including the first ablation and the second ablation.

29. The system of claim 28 , wherein the therapy head comprises:

an enclosure with a partition, the partition defining the first chamber and a second chamber within the enclosure; and

a motor assembly within the second chamber,

wherein the high intensity focused ultrasound transducer is movable within the first chamber through motor command provided to the motor assembly from the controller.

30. The system of claim 28 , wherein the data store further comprises information stored in library tables.

31. The system of claim 28 , wherein the data store further comprises profile data particular to various anatomical regions of adipose tissue.

32. The system of claim 31 , wherein the profile data is adapted for gender variations.

33. The system of claim 28 , wherein the therapy head is adapted for various anatomical regions of adipose tissue.

34. The system of claim 28 , wherein the controller is adapted to promote an effect of necrosis of adipose tissue.

35. The system of claim 28 , wherein the controller is adapted to promote an effect of denaturing collagen fibrils.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 9, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 063942/0001 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 13, 2021
From: AESTHERA; LIPOSONIX, INC.
To: SOLTA MEDICAL, INC.
Reel/Frame 056227/0174 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: LIPOSONIX, INC.
Reel/Frame 032126/0370 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: SILICON VALLEY BANK
To: LIPOSONIX, INC.
Reel/Frame 032126/0531 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: LIPOSONIX, INC.
To: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0454 →